Merck stops development of combination diabetes drug

11/19/2012 | Reuters

Merck & Co. cited business reasons in its decision to stop development of a diabetes pill that would have combined its Januvia and a generic version of Lipitor, Pfizer's cholesterol drug. Drugmakers see combination drugs as a way to reduce the number of medications patients take. Merck already markets Juvisync, which is Januvia plus the cholesterol drug simvastatin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA